1. Protein Tyrosine Kinase/RTK
  2. c-Fms
  3. Sotuletinib

Sotuletinib  (Synonyms: BLZ945)

Cat. No.: HY-12768 Purity: 99.78%
COA Handling Instructions

BLZ945 est un CSF-1R (c-Fms) inhibiteur puissant, sélectif et cerveau-pénétrant avec un IC50 de 1 nM, montrant plus 1 000 fois de sélectivité par rapport à ses homologues récepteurs tyrosine kinase les plus proches.

Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.

For research use only. We do not sell to patients.

Sotuletinib Chemical Structure

Sotuletinib Chemical Structure

CAS No. : 953769-46-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
10 mM * 1 mL in DMSO USD 99 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 99 In-stock
5 mg USD 90 In-stock
10 mg USD 140 In-stock
50 mg USD 280 In-stock
100 mg USD 480 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Sotuletinib:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review


Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs[1].

IC50 & Target

IC50: 1 nM (CSF-1R), 3.2 μM (c-Kit), 4.8 μM (PDGFRβ), 9.1 μM (Flt3)[1]

In Vitro

Treatment of bone marrow-derived macrophages (BMDMs) with Sotuletinib inhibits CSF-1-dependent proliferation (EC50=67 nM), and decreases CSF-1R phosphorylation, similar to CSF-1R antibody blockade. Sotuletinib also reduces viability of CRL-2467 microglia, Ink4a/Arf−/− BMDMs (PDG genetic background), and NOD/SCID BMDMs. Importantly, Sotuletinib treatment in culture does not affect proliferation of any PDG-derived tumor cell lines (all Csf-1r-negative), or U-87 MG human glioma cells, and PDG cell tumor sphere formation is unaffected. Thus, Sotuletinib has no direct effects on glioma cells, and perturbs macrophage survival through CSF-1R inhibition[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice are treated with Sotuletinib or vehicle, and evaluated for symptom-free survival. Median survival in the vehicle-treated cohort is 5.7 weeks. In striking contrast, Sotuletinib significantly improves long-term survival with 64.3% surviving to the 26-week trial endpoint. This endpoint is chosen because Ink4a/Arf−/− mice develop spontaneous tumors, including lymphomas and sarcomas, beginning at ~30 weeks. Sotuletinib is well-tolerated over long-term treatment, with no visible side-effects, consistent with histopathological studies. Histological grading revealed high-grade, invasive gliomas in all vehicle-treated mice. By contrast, Sotuletinib-treated animals have significantly less-malignant tumors, and no detectable lesions in 55.6% of asymptomatic mice at the endpoint[1]. Mice receiving Sotuletinib shows reduced CSF1R staining in both cervical tumors and the associated stroma, with a significant decrease in CSF1R+ stromal macrophages relative to vehicle-treated mice (P<0.05)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight







O=C(C1=NC=CC(OC2=CC=C3N=C(N[[email protected]]4[[email protected]](O)CCCC4)SC3=C2)=C1)NC


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 83.33 mg/mL (209.12 mM; Need ultrasonic)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5095 mL 12.5477 mL 25.0954 mL
5 mM 0.5019 mL 2.5095 mL 5.0191 mL
10 mM 0.2510 mL 1.2548 mL 2.5095 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  20% SBE-β-CD in saline

    Solubility: 10 mg/mL (25.10 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

  • 4.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 99.78%

Cell Assay

Cell growth rate is determined using the MTT cell proliferation kit. Briefly, cells are plated in triplicate in 96-well plates: 1×103 cells per well for glioma cell lines, 5×103 cells per well for BMDM and CRL-2467, and 2.5×103 cells per well for HUVEC and HBMEC cell lines. For all experiments, media is changed every 48 h. Cells are grown in the presence or absence of 6.7-6,700 nM of Sotuletinib, or 8 μg/mL of CSF-1R neutralizing antibody. To test the sensitivity to PDGFR inhibition, PDGC lines are cultured in the presence of 10,000 nM STI571 or 10,000 nM PTK787 (diluted from 10 mM stock solutions in DMSO). HUVEC and HBMEC cells are supplemented with ECGF supplied by the manufacturer unless otherwise indicated. Reduction of the MTT substrate is detected by colorimetric analysis using a plate reader as per the manufacturer’s protocol. 10 μL of MTT labeling reagent is added to each well and then incubated for 4 h at 37°C, followed by the addition of 100 μL MTT solubilization reagent overnight. The mixture is gently resuspended and absorbance is measured at 595 nm and 750 nm on a spectraMax 340pc plate reader[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Tumors are measured using calipers and volumes calculated based on the formula: volume=(width)2×length/2. In MMTV-PyMT mouse studies, 56-63 d old female mice are randomized into groups based on tumor volumes and dosed with either 20% Captisol vehicle or 200 mg/kg Sotuletinib. Dosing is administered by oral gavage once daily and tumor volumes are measured twice weekly. 5A1 rat anti-mouse CSF1 neutralizing antibody or rat IgG control is dosed at 10 mg/kg by intraperitoneal injection every 5 d. To calculate pulmonary metastasis in MMTV-PyMT transgenic mice, formalin-fixed paraffin-embedded lungs are serially sectioned and stained with hematoxylin and eosin. Tumor regions are scored by tumor burden (total tumor area divided by total lung area), size (tumor diameter), and according to the total number of individual metastases counted in a single-blind fashion. These values are averaged across the entire depth of the lung to obtain the final value.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name



Applicant Name *


Email address *

Phone number *


Organization name *

Department *


Requested quantity *

Country or Region *



Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:
MCE Japan Authorized Agent: